NGM Bio’s Merck-partnered drug for vision loss disorder flunks Phase 2 test
NGM Biosciences’ experimental geographic atrophy therapy failed a mid-stage test, making it less likely that drug partner Merck will exercise its option on the antibody. Meanwhile, an Apellis Pharmaceuticals drug for the same disorder is expected to receive an FDA decision by late November.